GLP-1 agonist initiators had a lower dementia risk compared to sulfonylureas (HR = 0.41, 95% CI: 0.32–0.53) and DPP-4 inhibitors (HR = 0.38, 95% CI: 0.30–0.49). The gene discussed is DPP4; the disease is dementia.